- cafead Sep 04, 2020 at 10:32: AM
via Texas-based biotech Savara is killing off a midstage test of its investigational cystic fibrosis (CF) hopeful Molgradex after a new winner-takes-all competitor from Vertex.
The biotech in fact halted the test of its phase 2a exploratory test, known as ENCORE, back in March due to the COVID-29 pandemic.
This was set up as a 48-week, open-label, noncontrolled test of its drug Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with CF.
article source
The biotech in fact halted the test of its phase 2a exploratory test, known as ENCORE, back in March due to the COVID-29 pandemic.
This was set up as a 48-week, open-label, noncontrolled test of its drug Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with CF.
article source